Please assess the completion status of the following clinical trial:

Trial Title: Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Destination Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The following are general criteria; more specific conditions are included in the study protocol:~* Subjects with advanced heart failure symptoms (NYHA Class IIIB or IV) who are:~  * On optimal medical management and are failing to respond; or~ * In Class III or Class IV heart failure and dependent on IABP and/or inotropes; or~ * Treated with ACE inhibitors or beta-blockers and found to be intolerant.~* Ineligible for cardiac transplant~* VO2max \<=14 ml/kg/min~* LVEF \<=25%~Exclusion Criteria:~The following are general criteria; more specific conditions are included in the study protocol:~* Evidence of, or risk factors for end-organ dysfunction that would make LVAS implantation futile~* Existence of factors that would adversely affect patient survival or function of the LVAS~* Intolerance to anticoagulant or antiplatelet therapies.~* Existence of any ongoing mechanical circulatory support other than intra-aortic balloon counterpulsation.~* Participation in any other clinical investigation that is likely to confound study results or affect study outcome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HeartMate II (Type: EXPERIMENTAL): Implantation of HeartMate II LVAS
- HeartMate XVE (Type: ACTIVE_COMPARATOR): Implantation of HeartMate XVE LVAS

Based on this trial design, predict the completion outcome and termination type (if applicable).